非结晶型轻链近端肾小管病:一种形态学表现多样的疾病
单中心回顾性分析2005至2021年12例轻链近端肾小管病(LCPT)患者,其中结晶型5例、非结晶型7例。两型临床表现相似,非结晶型诊断需结合免疫荧光轻链限制和电镜。9/12例接受克隆导向治疗,血液学缓解者(含全部非结晶型)肾脏结局改善。
要点
- 非结晶型LCPT形态学特征细微,需电镜与「无小管损伤的轻链过度重吸收」鉴别。
- 12例中7例诊断多发性骨髓瘤、5例诊断具有肾脏意义的单克隆丙种球蛋白病(MGRS)。
- 9/12例接受克隆导向治疗,达血液学缓解者肾脏结局改善,中位随访79个月。
核心结论
- 非结晶型LCPT因组织病理学特征细微可能被漏诊,需电镜与「无小管损伤的轻链过度重吸收」鉴别。
- 克隆导向治疗并获良好血液学缓解可改善两型的肾脏结局,但MGRS数据有限。
- 需多中心前瞻性研究以明确与不良结局相关的临床病理特征并优化MGRS治疗策略。
研究设计与样本
- 单中心回顾性病例系列,纳入2005至2021年12例LCPT患者,其中结晶型5例、非结晶型7例。
主要发现
- 中位年龄69.5岁(范围47-80)。
- 10例表现为CKD和显著蛋白尿,中位估算肾小球滤过率43.5 ml/min/1.73 m2,尿蛋白与肌酐比值328 mg/mmol。
- 肾活检时仅6例已知血液系统疾病;7例诊断多发性骨髓瘤,5例诊断MGRS。
- 所有病例结合血清/尿电泳和游离轻链检测均检出克隆。
- 结晶型与非结晶型临床表现相似;非结晶型诊断基于无其他原因的CKD、血液学检查、免疫荧光轻链限制和电镜异常。
关键数值与推荐
- 12例中9例接受克隆导向治疗。
- 达血液学缓解者(包括全部非结晶型LCPT)肾脏结局改善,中位随访79个月。
局限性
- 原文为单中心回顾性病例系列。
- MGRS数据有限。
- 需多中心前瞻性研究以更好定义与不良结局相关的临床病理特征并优化MGRS治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Light chain proximal tubulopathy (LCPT) is a rare form of paraprotein-related disease, occurring in two main histopathological forms: crystalline and non-crystalline. The clinicopathological features, treatment strategies and outcomes, especially of the non-crystalline form, are not well described. METHODS: We conducted a single-centre retrospective case series of 12 LCPT patients, 5 crystalline and 7 non-crystalline, between 2005 and 2021. RESULTS: The median age was 69.5 years (range 47-80). Ten patients presented with CKD and significant proteinuria (median estimated glomerular filtration rate of 43.5 ml/min/1.73 m2; urine protein:creatinine ratio 328 mg/mmol). Only six patients had known haematological disease at the time of renal biopsy. Multiple myeloma (MM) was diagnosed in seven patients cases and monoclonal gammopathy of renal significance (MGRS) in five patients. A clone was detected in all cases combining serum/urine electrophoresis and free light chain (LC) assays. Crystalline and non-crystalline variants had similar clinical presentations. For the non-crystalline variant, a diagnosis was reached based on a combination of CKD without another cause, haematological workup, LC restriction on immunofluorescence and abnormalities on electron microscopy (EM). Nine of 12 patients received clone-directed treatment. Patients who achieved haematological response (including all non-crystalline LCPT) had improved renal outcomes over a median follow-up of 79 months. CONCLUSIONS: The non-crystalline variant may go unrecognised because of its subtle histopathological features and requires EM to distinguish it from 'excessive LC resorption without tubular injury'. Clone-directed treatment with good haematological response improves renal outcomes in both variants but limited data exist in MGRS. Multicentre prospective studies are needed to better define the clinicopathological characteristics associated with poor outcomes and optimize treatment strategies in patients with MGRS.
引用
- Kousios A, Blakey S, Moran L, et al. Non-crystalline light chain proximal tubulopathy, a morphologically protean entity. Nephrol Dial Transplant. 2023. PMID: 37120733. doi:10.1093/ndt/gfad085
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。